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Abstract 
The glucocorticoid (GC) receptor (GR) and Kruppel-like factor Klf4 are transcription factors 
that play major roles in the skin homeostasis by regulating the expression of overlapping gene 
subsets. However, whether these transcription factors cooperate in binding genomic regulatory 
regions in epidermal keratinocytes was not known. Here, we show that in dexamethasone-
treated keratinocytes GR and Klf4 are recruited to genomic regions containing adjacent GR and 
KLF binding motifs to control transcription of the anti-inflammatory genes Tsc22d3 and Zfp36. 
GR- and Klf4 loss of function experiments showed total GR but partial Klf4 requirement for full 
gene induction in response to dexamethasone. In wild type keratinocytes induced to 
differentiate, GR and Klf4 protein expression increased concomitant with Tsc22d3 and Zfp36 
up-regulation. In contrast, GR-deficient cells failed to differentiate or up-regulate Klf4 and 
Zfp36 correlating with increased expression of the epithelium-specific Trp63, a known 
transcriptional repressor of Klf4. The identified transcriptional cooperation between GR and 
Klf4 may determine cell-type specific regulation and have implications for developing therapies 
for skin diseases. 
 
Key words: glucocorticoid receptor, Kruppel-like factor 4, keratinocyte, transcription, 
inflammation. 
 
Introduction 
Glucocorticoid (GC) hormones act through the GC receptor (GR), a ligand-dependent 
transcription factor (TF) that regulates gene expression in virtually all cell types. The 
mechanisms of GR action include transactivation, direct binding to GC responsive element 
(GRE)-containing genes; and transrepression, interference with other transcription factors 
through protein-protein interactions (1, 2). GR can also repress gene expression by directly 
binding to recently identified simple negative GREs and recruiting transcriptional corepressors 
(3). GR controls a vast array of physiological processes including modulation of the 
inflammatory response, as well as epidermal differentiation and homeostasis (2, 4). Identifying 
mechanisms for the tissue-specific actions of GR is of great interest due to the widespread use 
of GCs as therapeutic agents, such as in inflammatory skin diseases, where prolonged usage 
results in undesirable side effects, including skin thinning and delayed wound healing (1, 4). 
Combinatorial action of GR with cell type-specific TFs is a way to attain diverse 
physiological outcomes (5). While the majority of ligand-bound GR associates with pre-existing 
sites of open chromatin (6), it can also bind to transcriptionally silent chromatin acting as a 
“pioneer factor” (7). GR binding has been shown to facilitate the binding of other TFs via 
“assisted loading”, a process whereby GR-dependent recruitment of chromatin remodeling 
proteins change local nucleosome structure creating a more accessible state (8). 
The Krüppel-like family of transcription factors (KLF) is formed by a class of DNA-
binding proteins with a key role in development and physiology. KLF family members are 
known to functionally interact with other members of the nuclear hormone receptor 
superfamily, in a tissue specific fashion (9). Klf4 is critical for function of differentiated 
epithelial cells consistent with its high expression in the epidermal suprabasal layers (10). Klf4 
is also one of the four factors that reprogram differentiated cells to pluripotency (11). How Klf4 
is capable of regulating such diverse processes is not completely understood. Along these lines, 
a recent study in human keratinocytes demonstrated that Klf4 forms a complex with the 
epithelial-specific TF ZNF750 and chromatin regulators RCOR1 and CTBP1/2 to promote 
transcription of genes associated with terminal differentiation (12). 
Genetic experiments established that both GR and Klf4 are critical for establishing the 
skin’s barrier function. For instance, mice deficient in the expression of either Klf4 or GR have 
defective epidermal differentiation and permeability barrier acquisition (13, 14). Antenatal GC 
injections accelerate in utero barrier formation as does epidermal (keratin 5 (K5) promoter) 
overexpression of Klf4 (15, 16). The observation that GC treatment of developing K5-Klf4 mice 
further accelerated formation of the epidermal barrier suggested synergistic actions of GR and 
Klf4 (17). Further evidence for synergism was the identification of a gene subset similarly 
regulated by GC treatment or Klf4 overexpression (17). However, direct co-regulation of 
keratinocyte gene expression has not been demonstrated, in part due to the absence of a suitable 
model to evaluate GR-mediated gene regulation (14, 17). This has been recently overcome by 
the generation of GR epidermal knock-out (GREKO) mice in our group (18). Newborn GREKO 
epidermis showed aberrant expression of genes involved in epidermal barrier function, innate 
immunity and inflammation, many of which are also deregulated in inflammatory skin diseases, 
such as atopic dermatitis and psoriasis (18). These data suggest that GR may be a link between 
defective epidermal differentiation and inflammation during development.  
In postnatal skin, the role of GR and Klf4 has been evaluated using gain or loss of 
function models restricted to K5 or K14 expressing tissues. In the case of GR, overexpression 
results in resistance to epidermal inflammation and tumorigenesis (4, 19), while loss provokes 
an increased sensitivity to inflammatory stressors and skin carcinogenesis (18, 20). Likewise, 
inducible deletion of Klf4 in the epidermis results in increased DMBA/TPA induced 
tumorigenesis (21). Inducible activation of Klf4 in the epidermal basal layer unexpectedly 
resulted in epithelial dysplasia (22), though this discrepancy may be due to the fact that 
depending on cellular context Klf4 can act as a tumor suppressor or oncogene (23). 
In this study, we present evidence demonstrating that GR and Klf4 are recruited to GC- 
and KLF-responsive elements on a subset of GC-regulated genes to modulate transcription in 
keratinocytes. Both TFs bind to regions near the anti-inflammatory genes Tsc22d3 and Zfp36, 
and cooperate in their regulation. Furthermore, we found that Tsc22d3 and Zfp36 are up-
regulated during keratinocyte terminal differentiation, suggestive of a link between regulation of 
inflammatory processes and terminal differentiation, or of novel roles for these genes in 
keratinocytes. As Klf4 is enriched in epithelial cells, it is conceivable that GR preferentially 
uses the GR binding sites (GBSs) adjacent to KLF sites in keratinocytes as a mechanism 
determining cell-type specific regulation.  
 Materials and Methods 
Reagents and antibodies 
Unless otherwise specified all chemicals are from Sigma-Aldrich. Primary antibodies used were 
specific for GR (sc-1004), Klf4 (sc-20691), p63 (sc-8431, Santa Cruz Biotechnology), phospho- 
GR Ser 211 (4161S, Cell Signaling Technology), tubulin (T6199, Sigma-Aldrich). Peroxidase-
conjugated secondary antibodies were from GE HealthCare. HRP-conjugated Clean-blot IP 
Detection Reagent was used for immunoblotting immunoprecipitation experiments and was 
from Thermo Scientific. Secondary Alexa Fluor- conjugated secondary antibody was from Life 
Technologies.  
 
Cell culture 
Mouse primary keratinocytes (MPKs) were isolated and cultured as described (24), using 
complete EMEM: EMEM (Lonza) supplemented with 4% FCS (Biowest) previously treated 
with Chelex 100, 100 U/ml penicillin/100 g/ml streptomycin (Biowest) and 2.5 g/mL 
amphotericinB (Biowest). The skin of newborn (P0-P3) wild type mice was incubated in 0.25% 
trypsin at 4oC overnight. The epidermis was separated from the dermis, minced, and 
homogenized in complete EMEM with 0.05 mM CaCl2. Samples were pooled and the resulting 
suspension was filtered through a cell strainer (BD Biosciences). Cells were counted and plated 
on collagen I (Gibco)-coated culture dishes in complete EMEM with 0.6 mM CaCl2. The 
following day, cells were washed with DPBS (Biowest) and incubated in complete EMEM with 
10 ng/mL EGF (Peprotech) and 0.05 mM CaCl2 until nearly confluent. 
  GREKO and control keratinocyte cell lines were generated from 8-wk-old female mouse 
dorsal skin as previously described (18) and cultured on mitomycin C treated J2-3T3 feeders in 
collagen I-coated flasks in DMEM-Ham’s F12 (3:1) medium (Gibco) supplemented with 1.8 × 
10−4 mol/L adenine, 0.35 mM calcium, 7.5% FCS, 100 U/ml penicillin/100 g/ml streptomycin 
(Biowest), 2 mM glutamine (Biowest), 0.25 g/mL amphotericinB (Biowest), 5 g/ml insulin, 
10-10 M cholera toxin and 10 ng/ml EGF (Peprotech).  
 Prior to treatment with 100nM Dex, to deplete steroid hormones, cells were grown for 
18-24 h in respective medium containing charcoal-stripped serum. To induce terminal 
differentiation, keratinocytes were incubated with medium containing 1.2 mM CaCl2.  
 
Chromatin Immunoprecipitation and ChIP-seq 
ChIP experiments were performed as previously described (24), using MPKs or adult 
keratinocyte cell lines grown to confluency in 100 mm culture dishes (Thermo Scientific). 
Keratinocytes were incubated with freshly prepared 1% formaldehyde 8 minutes at room 
temperature, lysed and sonicated using the Bioruptor (Diagenode) to fragment chromatin. 
Immunoprecipitation was done with 3 g of the indicated antibodies and Dynabeads Protein A 
(Life Technologies). After ChIP, reversion of cross-linking, and treatment with proteinase K 
and RNase, DNA was purified by phenol-chloroform extraction. Glycogen (Roche) was added 
to visualize pellet. QPCR (see below) was performed to assess the relative amplification of 
specified genomic sites in Dex vs mock-treated ChIPs, which were normalized to the 
amplification values of respective inputs. At least three biological replicates were used for each 
experimental group and technical triplicates were assessed to calculate the mean value ± SD. 
Statistical significance was calculated using the Student’s t test. 
GR ChIP-seq was performed as indicated by the manufacturer (Illumina-Solexa, 
http://www.illumina.com) (25). The quality of Input and ChIP DNA was first verified by 
Bioanalyzer (Agilent). Then, for library generation, oligonucleotide adapters were added to the 
DNA fragments which were then subjected to amplification and size selection. The resulting 
DNA quality was tested by QPCR at identical genomic regions as the original DNA. Next, 
DNA was sequenced by the Genome Analyzer II (Illumina) and data files processed using two 
different sequence alignment tools (Novoalign and MAQ) along with three different peak callers 
(SISSR, PeakRangers and MACS). The 123 selected peaks are those which had overlap 
between all algorithms and therefore are of high confidence (Table S1). 
Peaks were assigned to genes using GREAT software. Gene ontology of genes with 
assigned peaks was carried out using DAVID (http://david.abcc.ncifcrf.gov/). Search of the 
transcription factor binding motifs in identified GR-bound regions was done using MEME 
(http://meme.nbcr.net/meme/). 
 
RNA isolation and Quantitative RT-PCR 
Total RNA was isolated from cultured keratinocytes using Trizol (Life Technologies). RNA 
was treated with DNase (Thermo Scientific), for later use with primer pairs which bind within 
the same exon, and reverse transcribed using RevertAid H Minus Reverse Transcriptase and 
oligo dT primers (Thermo Scientific). QPCR using specific oligonucleotides (Table S2) and 
FastStart Universal SYBR Green Master ROX (Roche) was carried out in an Applied 
Biosystems 7500 Fast real time PCR system. At least three biological replicates were used for 
each experimental group and technical triplicates were assessed to calculate the mean value ± 
SD. Statistical significance was calculated using the Student’s t test.  
 
Klf4 knockdown 
Keratinocytes were transfected with 25 nM Klf4 specific (L04001010005) or Control 
(D0018101005) On-Target plus siRNA Smartpool (Thermo Scientific) using Lipofectamine 
2000 (Life Technologies) and Optimem medium (Life Technologies). Transfection was carried 
out in DMEM-Ham’s 12 medium without antibiotics or antimycotic. Medium was changed 5 
hours after addition of siRNA-Lipofectamine 2000 complexes. Experiments were conducted 48 
hours following transfection.  
 
Immunoblotting 
Keratinocytes were lysed in RIPA buffer (50 mM Tris HCl pH 8, 150 mM NaCl,1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS) and samples were boiled in Laemmli buffer and 
separated on 8% SDS-PAGE (25 µg/lane), then transferred to nitrocellulose membranes 
(Hybond ECL, GE Healthcare). Membranes were stained with Ponceau S to verify equal 
protein loading and transfer. Membranes were blocked with 5% nonfat dry milk in PBS-0.1% 
Tween 20, and incubated with primary antibodies overnight at 4oC. After washing three times 
in PBS-0.1% Tween 20, membranes were incubated with peroxidase-conjugated secondary 
antibodies, washed again, and analyzed using ECL2 (Thermo Scientific) with the ImageQuant 
4000 Biomolecular Imager (GE Healthcare). Experiments were quantitated using Image J 
software and were performed with a minimum of at least three biological replicates. 
 
Immunoprecipitation 
Keratinocytes were lysed in buffer containing 50 mM Tris pH 7.6, 150 mM NaCl, 5 mM 
EDTA, 0.5% Igepal CA-630 with protease and phosphatase inhibitors (Roche). Proteins were 
immunoprecipitated using 2g of Klf4 specific antibody or rabbit IgG as a negative control and 
Dynabeads Protein A (Life Technologies). Following washing with buffer containing 0.2% 
Igepal CA-630, proteins were eluted from beads by boiling in Laemmli buffer for analysis by 
immunoblotting. 
Results and Discussion 
 
To understand how GR transcriptionally regulates keratinocyte homeostasis and differentiation, 
we performed ChIP-sequencing (ChIP-seq) analysis in mouse primary keratinocytes (MPKs) 
that were treated either with vehicle or Dex for 2h. Following peak calling, we identified GR 
bound to 123 regulatory sequences upon Dex treatment (Table S1). 
 Our data identified a limited number of GBSs relative to other ChIP-seq approaches 
that reported GBSs were within the range of thousands (26-28), however, subsequent validation 
confirmed the accuracy of the data (see below). The identified GR ChIP-seq peaks corresponded 
to both known and novel GR-target genes in keratinocytes. The anti-inflammatory genes 
Tscd22d3/Gilz and Zfp36, the circadian rhythm gene Per1, and the receptor tyrosine kinase-like 
orphan receptor Ror1, among others, have been previously reported as GR-targets in other cell 
types (29). In keratinocytes, these genes are known to be regulated by Dex, though the precise 
binding sites of GR and the mechanism of regulation in this cell type were unknown (30). 
Importantly, the relatively small number of GBSs identified in our ChIP-seq is in agreement 
with the finding that few genes were detected as having changes in expression in human 
keratinocytes treated with Dex for 1 or 4 h, as compared to later time-points where the 
expression of hundreds of genes was altered (30). 
We first confirmed the regulation of identified genes by hormone-activated GR in an 
independent experiment in MPKs. ChIP of Dex or mock-treated (2h) cells using an anti-GR 
antibody followed by quantitative (Q)-PCR demonstrated direct, ligand dependent recruitment 
of GR to putative regulatory sequences of Per1, Tscd22d3 and Zfp36 (Fig. 1A). Differences 
were statistically significant, as assessed by Student's t test. Consistently, Tscd22d3 and Per1 
expression was induced by 6-fold or more and Zfp36 by almost 2-fold after hormone treatment 
(Fig. 1B). These results validated our ChIP-Seq data and confirmed that the identified high 
confidence peaks were “true” GR primary targets. 
To overcome the inherent difficulties in working with primary keratinocytes (17), we 
established spontaneously immortalized adult keratinocyte cell lines (20). There are differences 
in the basic biology of keratinocytes depending on the developmental stage and whether they 
are primary or immortal (31). Therefore, we evaluated whether Dex treatment induced similar 
GR recruitment and gene expression changes in our control adult cell line (CO) relative to 
primary newborn keratinocytes. We focused on Tsc22d3 and Zfp36 because they are known 
anti-inflammatory genes whose regulation and function in the epidermis are not well 
understood. Indeed, both GR recruitment (Fig. 1C) and gene induction of Tscd22d3 and Zfp36 
(Fig. 1D, CO) occurred to a similar extent in the adult keratinocyte cell line as observed in 
newborn primary cells (Fig. 1A,B), indicating that in the case of these genes developmental 
stage (or primary or immortal status) does not affect regulation by GCs. We used a GR deficient 
cell line derived from adult GREKO epidermis to unequivocally determine the dependence of 
Dex-induced changes in gene expression on this TF (Fig. 1E; 20). In GREKO cells, neither 
Tsc22d3 nor Zfp36 were induced by Dex, showing that the presence of GR is necessary for this 
process (Fig. 1D, GREKO). 
We searched the identified GR ChIP-seq peaks for the presence of consensus GRE 
(AGAACAnnnTGTTCT) using MEME (http://meme.nbcr.net/meme/) and found GRE motifs in 
64% of putative regulatory regions (Table S1). Considering that GR binds to composite 
elements, we searched for co-occurrence of binding motifs of other TFs in the sequences of the 
GR bound peaks. In the 123 sequences analysed, several over-represented TF motifs, including 
KLF (43%) and AP-1 (28%) were identified (Table S1). 
GR transrepression of AP-1 dependent transcription is well known, especially in the 
regulation of genes associated with inflammation (29). However, AP-1 can also facilitate the 
accessibility of GR to genomic binding sites by maintaining the chromatin in a more accessible 
conformation (32). In contrast, there are fewer examples for functional interactions between GR 
and KLFs, which occur in a tissue specific fashion, due to differing expression patterns of 
individual KLF members (9, 33). For instance, Klf11, in a neuronal cell line and Klf15 in a lung 
cell line were found to co-bind with GR to regulatory regions of target genes (34, 35). A very 
recent study in macrophages identified GR and KLF binding sites in genes encoding Klf2 and 
Klf9 and in the GR targets Cited and Mt2 (33). Our ChIP-Seq data also suggest that GR and 
KLFs co-regulate a KLF member, as putative sites for both TFs were identified in Klf13 (Table 
S1). Aside from these specific examples, the significance of the cooperation between KLFs and 
GR is still limited.  
We next focused on Klf4 as a possible candidate for binding KLF motifs in the 
identified regions bound by GR given the known involvement of both TFs in epidermal 
development and homeostasis. Comparison of previous gene expression studies has shown an 
extensive overlap between genes regulated by GR and Klf4, mostly related to epidermal 
differentiation (17, 18, 24, 36). Additionally, there is an overlap between direct GR targets 
identified here and Klf4 regulated genes in human keratinocytes (Table S1; 37).  
GR-bound sequences near Tscd22d3 and Zfp36 contained consensus GREs as well as 
adjacent KLF motifs (Table S1 and Fig. 2A). We assessed Klf4 recruitment to putative Tsc22d3 
and Zfp36 regulatory regions by ChIP-QPCR and found statistically significant increases in 
Klf4 binding to both (4.7-fold and 2.9-fold, respectively) upon Dex treatment of control cells 
(Fig. 2B). In GR-deficient keratinocytes, in the case of Tsc22d3, Dex-dependent recruitment of 
Klf4 was decreased by almost 3-fold relative to that observed in control cells. The slight 
induction (1.7 fold) of Klf4 binding to Tsc22d3 in Dex-treated GREKO cells, was not statistically 
significant but may reflect a role of the mineralocorticoid receptor, closely related to GR and 
able to bind GCs. Importantly, the binding of Klf4 to Zfp36 was greatly reduced both in the 
absence and presence of Dex (0.22 fold and 0.39 fold, respectively) in GREKO relative to control 
cells (Fig. 2B). The Dex- and GR-dependent recruitment of Klf4 to both genomic regions 
suggests cooperation between both TFs in regulating these anti-inflammatory genes. Given that 
several KLFs promote the anti-inflammatory program in macrophages, functional cooperation 
between GR and this family of TFs was postulated as a mechanism to counteract inflammation 
in these cells (33). 
To further analyze the contribution of Klf4 to the regulation of Tsc22d3 and Zfp36, we 
transfected the control cell line with siRNA specific for Klf4 and achieved approximately 60% 
knockdown (Fig. 3). Dex-induction of Tsc22d3 was decreased by approximately 2-fold in cells 
expressing the Klf4 siRNA relative to control siRNA. Our results demonstrate that not only GR 
but also Klf4 is required for induction of Tsc22d3 in the presence of Dex. While Klf4 was 
required for Tsc22d3 induction, decreased Klf4 levels did not affect that of Zfp36. This may be 
due to incomplete knockdown or to a different role of Klf4 in the regulation of this gene. 
There is controversy regarding whether GCs regulate Klf4 gene expression in epidermal 
keratinocytes. While Klf4 mRNA was not up-regulated by antenatal GC treatments in 
developing mouse skin (17), it was induced by Dex treatment of cultured human keratinocytes 
(30). We assessed Klf4 basal gene expression in adult cell lines and found decreased mRNA 
levels in GREKO vs control cells (Fig. S1); however, no Klf4 induction was found in control 
keratinocytes treated with Dex for 3 to 24h (Fig. 3 and data not shown). In contrast, in other cell 
types such as macrophages, Klf4 is induced by Dex treatment possibly through GR recruitment 
to two putative GREs located at −3830 bp and +5896 bp relative to the Klf4 transcription start 
site (33). These differences may be due to cell-type specific expression of co-regulators. 
We also evaluated whether GR and Klf4 associated upon treatment with Dex (Fig. S2). 
While a small amount of GR was detected in Klf4 immunoprecipitates in the absence of 
hormone, it did not increase upon Dex treatment, indicating a mechanism other than direct 
protein-protein interaction for GC-induced recruitment of Klf4 (Fig. S2). We speculate that the 
mechanism of Klf4 recruitment could be similar to the Dex-induced de novo remodeling of 
chromatin near GR binding sites (enriched for canonical GREs) and assisted loading of the TF 
C/EBP observed in liver (28).  
 It is well known that treatment of cultured keratinocytes with high calcium 
concentrations (1.2 mM) induces cell differentiation. Consistent with its role in terminal 
differentiation, Klf4 is induced in human primary keratinocytes grown in high calcium medium 
for 72h (37). GR protein has also recently been described to be up-regulated in keratinocytes 
cultured in high calcium conditions (38). To evaluate whether Klf4 induction can compensate 
for the loss of GR in keratinocytes, confluent control and GREKO cells were grown in high 
calcium (1.2 mM) containing medium for 0 or 72h (Fig. 4). Control keratinocytes underwent 
terminal differentiation in the presence of high calcium, featuring cell flattening, extensive cell-
cell contacts, stratification and formation of cornified envelopes (Fig. 4A; asterisks). The 
expression of the differentiation marker Sprr2d was strongly induced in calcium-treated control 
cells, as shown by RT-QPCR (Fig. 4B). In contrast, GREKO cells showed an aberrant 
morphology featuring spindle-like phenotype with decreased cell-cell contacts even in low 
calcium conditions (Fig. 4A). In high calcium medium, GREKO cells failed to properly 
differentiate, as seen by the lack of cornified envelopes (Fig. 4A) which was further confirmed 
by the lack of Sprr2d induction (Fig. 4B). 
Importantly, neither Klf4 mRNA nor protein was induced in calcium treated GREKO 
cells, whereas both were induced in the control (Figs. 4B and 5C,D). We did not observe Nr3c1 
up-regulation in terminally differentiated control cells; however GR protein levels did show a 
modest increase in agreement with Yoon et al. ((38); Figs. 4B and 5C,D). Notably, we observed 
an increase of Tsc22d3 and Zfp36 expression in differentiating control cells (Fig. 4B). In 
contrast, in GREKO cells, calcium treatment did not result in up-regulation of Zfp36; and Tsc22d3 
showed a 3-fold decrease in induction relative to the control (Fig. 4B). We postulate that the 
decreased induction of these genes, in addition to that of Klf4, in GREKO cells may interfere with 
keratinocyte differentiation. For instance, the negative signaling of TSC22D3 on the 
RAS/RAF/ERK pathway (1, 2) could be important in halting proliferation during 
differentiation. While ZFP36 is best known for destabilization of Tnf and Csf2, currently there 
are more than 40 known targets including a wide range of cytokines, which can affect 
keratinocytes, and factors involved in cell cycle control such as Cyclin D1 (39). 
As Klf4 expression was not affected by short treatments with Dex (Fig. 3), we 
considered other mechanisms for its misregulation in GREKO cells. We previously observed that 
Np63 expression, the predominant isoform of Trp63 in epidermis (40), was reduced in oral 
epithelia of K5-GR transgenic mice, suggesting negative regulation by GR (41). Importantly, 
Np63 represses Klf4 expression by directly binding its promoter (42), and the expression of 
both TFs is mutually exclusive in the epidermis, with Np63 expressed basally and Klf4 
suprabasally. We evaluated whether GR could regulate Klf4 indirectly by modulating p63 
expression, first by testing whether p63 isoform levels were affected by Dex in control and 
GREKO cell lines (Fig. 5A). The levels of both Np63 and TAp63 were diminished by Dex in 
control keratinocytes while no effect was observed in GREKO cells (Fig. 5A). These data show 
that activated GR is capable of repressing the expression of Trp63 isoforms. Strikingly, TAp63 
levels were elevated by 2-fold in GREKO relative to control cells (Fig. 5A). While TAp63 has 
tumor suppressor properties (43), inducible epidermal overexpression causes hyperproliferation 
and a failure to commit to terminal differentiation (44), indicating functions dependent on 
cellular context and on the ratio to the Np63 isoform. 
We next examined the expression of p63 isoforms in control and GREKO keratinocytes 
grown in high calcium medium for 72 h (Fig. 5B). Here, we observed an increased expression 
of both Np63 (1.8-fold) and TAp63 (6.6-fold) isoforms in GREKO cells prior to incubation with 
calcium. As the calcium experiments are done in the presence of complete serum and the Dex 
treatments with charcoal-stripped serum, it is likely that other lipophilic compounds may 
participate in the basal regulation of Np63. In the presence of calcium, Np63 was up-
regulated in GREKO keratinocytes, while TAp63 expression was not affected (Fig. 5B). 
Importantly, immunoblotting experiments confirmed the results of the RT-QPCR experiments 
(Fig. 5C, D). Since Zfp36 is a p63-target gene (45), it is feasible that the reduced Zfp36 mRNA 
levels detected in GREKO cells upon high calcium are not only due to the lack of GR but also to 
the augmented p63. 
A major aim in the field is to understand how individual or combined TFs modulate 
transcriptional programs in epidermal development and disease. Until now, two genome wide 
chromatin binding studies have been done for Klf4 in keratinocytes but none for GR (12, 46). 
This study provides the first direct evidence that GR and Klf4 bind at genomic regulatory 
regions near the anti-inflammatory genes Tsc22d3 and Zfp36. Our observation that these genes 
were up-regulated during keratinocyte terminal differentiation in a GR-dependent manner is 
suggestive of roles beyond modulating inflammation. GC treatment is a standard therapy for 
countering skin inflammation, with GR activation suppressing inflammatory pathways in both 
keratinocytes and skin immune cells (4). In immune cells, Klf4 can mediate inflammatory 
signaling (47-49), however, whether it does so in keratinocytes was unknown. Taken together, 
our data shows direct cooperation between Klf4 and GR in keratinocyte gene regulation and 
uncovers a role for Klf4 in regulating anti-inflammatory genes in these cells. 
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Figure legends 
 
Figure 1. Tsc22d3 and Zfp36 are direct GR transcriptional targets in keratinocytes 
Experiments were performed in cultured mouse primary keratinocytes MPKs (A, B) or 
immortal adult keratinocyte cell lines (C, D). 
A  GR ChIP-QPCR demonstrates recruitment to putative regulatory sequences of Per1, 
Tsc22d3, and Zfp36 upon Dex treatment (100nM, 2h). Fold GR recruitment (mean values ± SD) 
in Dex- vs mock- treated MPKs is shown, with asterisks denoting statistically significant 
differences between groups (Student’s t-test, n=3; *p<0.05, **p<0.01). 
B  Dex treatment (100 nM, 3h) induces gene expression of Per1, Tsc22d3, and Zfp36 in MPKs 
as measured by RT-QPCR. Relative gene expression (mean values ± SD) in Dex- versus mock-
treated samples is shown, with asterisks denoting statistically significant differences between 
groups (Student’s t-test; n=3; **p<0.01). 
C  GR ChIP-QPCR demonstrates recruitment to putative regulatory sequences of Tsc22d3 and 
Zfp36 upon Dex treatment (100 nM, 2h) in control cell line. Fold GR recruitment (mean values 
± SD) in Dex- vs mock- treated cells is shown, with asterisks denoting statistically significant 
differences between groups (Student’s t-test, n=4; *p<0.05, **p<0.01). 
D  Gene expression of Tsc22d3 and Zfp36 in Dex- (100 nM, 3h) or mock-treated GREKO and 
control (CO) cell lines was assessed by RT-QPCR. Relative gene expression (mean values ± 
SD) in Dex- versus mock-treated samples is shown, with asterisks denoting statistically 
significant differences between treatment groups (Student’s t-test; n=3; *, p<0.05; **, p<0.01). 
E  GR deficiency in the GREKO relative to the control cell line (CO) is shown by 
immunoblotting. Tubulin was used as a loading control.  
 
 
Figure 2. Klf4 is recruited to Tsc22d3 and Zfp36 in Dex-treated cells in a GR dependent 
manner. 
A  Genomic sequences near Tsc22d3 and Zfp36 to which ligand-bound GR was recruited in 
ChIP-seq. GREs and adjacent KLF and/or AP-1 sites are underlined. 
B  Klf4 recruitment to regions near Tsc22d3 and Zfp36 increases upon Dex treatment (100 nM, 
2h) in control but not in GREKO cells. Fold Klf4 recruitment (mean values ± SD) in Dex- relative 
to mock-treated CO and GREKO cells is shown, with asterisks denoting statistically significant 
differences between treatment groups (Student’s t-test; n=4; *, p<0.05; **, p<0.01). 
 
 
Figure 3. Knockdown of Klf4 interferes with Dex-induction of Tsc22d3 but not Zfp36. 
Tsc22d3 and Zfp36 showed statistically significant increases in expression following treatment 
with Dex (100 nM, 3h) in cells transfected with control but not Klf4 siRNAs as shown by RT-
QPCR. Note the reduction of Klf4 levels in samples transfected with gene specific siRNA. Fold 
change (mean values ± SD) in expression relative to mock-treated control siRNA transfectants 
is shown, with asterisks denoting statistically significant differences between treatment groups 
(Student’s t test; n=4; *, p<0.05; **, p<0.01). 
 
Figure 4. Defective calcium-induced terminal differentiation in GREKO cell line.  
A  Phase contrast images show morphological characteristics of calcium-induced differentiation 
in control (CO) but not GREKO cells after 72h in the presence of 1.2 mM calcium. Note the 
presence of cornified envelopes in control cells (asterisks) in contrast to striking defective 
differentiation of the GREKO cells. Bar: 50 m.  
B  Gene expression of Sprr2d, Nr3c1, Klf4, Tsc22d3, and Zfp36 in CO or GREKO cells treated 
for 0 or 72h with 1.2 mM calcium was assessed by RT-QPCR. Changes in gene expression 
(mean values ± SD) relative to t0 are shown, with asterisks denoting statistically significant 
differences relative to untreated controls (Student’s t-test; n=4; *, p<0.05; **, p<0.01). The 
graph has a logarithmic scale. 
 
Figure 5. GR negatively regulates Trp63 isoforms in keratinocytes. 
A  RT-QPCR shows that Dex-treatment (100nM, 3h) repressed expression of Trp63 isoforms 
Np63 and TAp63 in CO but not in GREKO cells. Note the elevated levels of TAp63 in GREKO 
relative to CO cells. Mean values ± SD are shown, with asterisks denoting statistically 
significant differences relative to mock-treated (V) samples (Student’s t-test; n=3; *, p<0.05; **, 
p<0.01).  
B  Np63 and TAp63 isoforms show elevated expression during calcium-induced terminal 
differentiation in GREKO versus CO cells as measured by RT-QPCR. Mean values ± SD are 
shown, with asterisks denoting statistically significant differences in GREKO relative to CO cells 
at each time-point (Student’s t-test; n=3; *, p<0.05; **, p<0.01). 
C  Immunoblotting shows induction of GR and Klf4 protein during terminal differentiation in 
CO but not in GREKO cells. Note the increase in p63 in GREKO cell extracts. Tubulin was used as 
a loading control. 
D.  Quantification of immunoblotting experiments. Mean values ± SD are shown, with asterisks 
denoting statistically significant differences between 0 and 72 h of calcium treatment within a 
genotype (Student’s t-test; n=3; *, p<0.05; **, p<0.01), and hashes denoting statistically 
significant differences in GREKO relative to CO cells at each time-point (Student’s t-test; n=3; #, 
p<0.05; ##, p<0.01). 
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Figure S1- Reduced Klf4 expression in GREKO versus CO cells.
Klf4 expression was assessed in GREKO versus CO cells by RT-QPCR.
Mean values ± SD are shown, with asterisks denoting statistically significant differences
in GREKO relative to CO (Student’s t-test; n=3; *, p<0.05).
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Figure S2- Evaluation of GR-Klf4 interaction via co-immunoprecipitation.
Lysates of cells treated with Dex for 0, 30 or 60 min were subjected to immunoprecipitation with antibody
specific for Klf4 or a nonspecific rabbit IgG (t0). Input controls and immunoprecipitates were analysed by
immunoblotting with GR, p-GR and Klf4 antibodies.
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Blot:
Gene symbol Chrom Chrom_start Chrom_end pvalue (‐10*log10) GRE MOTIF KLF MOTIF AP1 MOTIF
Per2 chr1 93332598 93333431 227,42 GTGTACAGAATGTTCCTGGC ACCCTCCCAACACA
Ralb chr1 121405904 121406699 375,29 AGGGACAGAGAGTCCAGGAC CTGACTCA
Nuak2 chr1 134231906 134232468 335,65 GGCGGGATCATGATGTTCTT TGAGGCAC
Gpr161 chr1 167221433 167222346 521,77 GGCCTGGGGCAGAG
AK017125 chr1 174479598 174480468 408,64 AGGGACAGAGAGTTCCTCAC TTCGACCACACCCC
Mthfd1l chr10 6240400 6241159 375,8 ACACAGCACATAGTGTTCCT AGTGTCTGGGAAGG
Moxd1 chr10 24115658 24116564 437,16 TCAGAGGACAGTATGTACTG
Anapc16 chr10 59436557 59437575 968,69 AGCCAGAACACAATGTTCTC TGAGAGGGGAGCAG
Unc5b chr10 60267884 60268713 291,1
Lrrc20 chr10 60927495 60928398 601,34 GCAGGGCACTCTGTGTACCC TCGGGCCACACCCA
Eif4ebp2
Mknk2 chr10 80126961 80127794 557,47 AGGAACAGCTCGTCCTAGGA
Spred2 chr11 19749542 19750339 338,36
Phf15 chr11 51729371 51730267 1887,93 CAGGACACCCAGTCCTTGGC ATGGGCCTCACACC
Cdkn2aipnl
Per1 chr11 68910113 68911085 852,61 AGAACACGATGTTCC CCCTGCCCCACATT
Krt42 chr11 100148051 100148802 306,78 CCGCACCCCACCCA
Eif1
Axin2 chr11 108872438 108873630 2554,95 ACGTGCCCCTCTCT
Rgs9
Sphk1 chr11 116394671 116395715 334,06
Bahcc1 chr11 120113752 120114488 432,05 GGGGTGGGGCAGAA
Id2 chr12 25854455 25855011 582,92 CCTGAGCACTCGGTGTTCCT GTGACTCA
Tmx1 chr12 71725183 71726107 265,87 AGGGTGTGGCCAGG
Frmd6
Fntb chr12 77984680 77985374 540,5 AGGATCAGAATGTTCTGTAG AGGGTGAGGCCCAG
Sel1l chr12 93117244 93117946 537,46 ACGAACATTCTGTCCCAGAA ATGACTCA
Rin3 chr12 103566223 103566907 258,14 AAGTACATTGTGTCCTTTGA AGGGTGGGGGTGGG
Klf6 chr13 5840515 5841102 467,77 ACCTTCCACTCCCT
Edn1 chr13 42469301 42470237 833,31 AGCAGGGACACTGTGTTCCA CACTTCCCCTCCCT
Jarid2 chr13 44964462 44965677 610,17
Gadd45g chr13 52001157 52001951 346,71 CCCAGCCCTACACT
AK014969 chr13 52344718 52345676 595,48 ATGAACACGATGTTCCCTGA
Diras2
AK144747 chr13 90653286 90654112 332,96 TCCCAGCACGGGGTGTTCTT ATGACTCA
Atp6ap1l
Hexb chr13 97960232 97961100 581,96 TCTCAGGACCGACTGACCCA
Grhl2 chr15 37122163 37122985 699,67 GGGAACACTGTGTCCTTGTA ATGACTCA
Azin1 chr15 38386738 38387747 326,58
Eif3h chr15 51561900 51562839 1048,8
AK163289 chr15 61439440 61440444 315,03
Micall1 chr15 78961713 78962462 364,9 AGTCACAGAATGTCCTTGGC GTGACTGA
Krt6a chr15 101527667 101528519 696,28 GCACTGCTCACTTTGTTCCC
Zc3h7a chr16 11143747 11144537 1228,4 GGCGTCGGGACCGG
Parn chr16 13506704 13507717 408,05 ACTTGCCCCACCCA
Gnb1l chr16 18547751 18548560 687,23 TGAGTCA
AK053957 chr16 25058959 25060033 545,38 CCGGGCCCCTCCCA
Leprel1 chr16 26248772 26249554 329,44 TAGAACATTGTATTCTTGGC TGAGTCAT
Cldn1
AK029404 chr16 31598510 31599566 427,38 AGGTACATCCAGTCCTGAGC
Sidt1 chr16 44233136 44233676 385,25 TGGTACAATTTGTGCCTGGT TGAGTCAC
Gm608
Cblb chr16 52094514 52095248 326,83 AAGTACAGACTGTCCCAGGA TGAGTCTC
Filip1l chr16 57391129 57392285 2087,76
N6amt1 chr16 87267971 87268910 902,63 GTCTGGCACTCACTCATCCA TCCTGCCTGTCCCC GTGACCCA
BC099513 chr16 95462765 95463864 659,75 TCACGGAACATATTGTACCT
Ets2 chr16 95880846 95881801 645,89
Hsf2bp chr17 32048871 32049713 813,46 GGGAACATTCCGTCTCGGAA
H2-T3 chr17 36367717 36368869 1320,18 CCCTCTCCCTCCCC
AK138323
Mir715 chr17 39979485 39986313 3100
Mir715 chr17 39979485 39986313 3100
Mir715 chr17 39979485 39986313 3100
Mir715 chr17 39979485 39986313 3100
Mir715 chr17 39979485 39986313 3100
Tcf4 chr18 68851589 68851983 633,78
Mc2r
AK009639 chr19 5849726 5850617 1565,36 AGGTACATTCCGTTCCAGGC TGGGCTGGGCCGGG
Hoga1 chr19 42132697 42133507 527,69 GGCCATCACACCGTGTTCCT GTGACTCA
Camk1d chr2 5299883 5300572 692,92
4921504E06Rik chr2 19501239 19502198 240,9 AGACAGAATGCTCTGTTCAG GTGACTCA
Pax8 chr2 24295381 24296340 475,02 GGAGGGCACATGATGTACAA
Itgb6 chr2 60537740 60538748 1361,25 CTGTACATTCTGTGCTGCTT TGAGTGAGGAGAGG
Tcp11l1 chr2 104545348 104546337 540,82 GGGAACAATTTGTGCTTTAG
Bcl2l1 chr2 152645660 152646435 420,7 TGAAGGGACACTGTGTTCCC
Pxmp3 chr3 5860456 5860990 2237,96
Zbtb7b chr3 89182266 89183149 544,95 AGGAACAAGACATTCCCTGC TGAGTCA
S100a10 chr3 93359704 93360284 314,37 TAGCACAAAGGGTTCCTGGA TGGGTGTGGCCTAG GTGACTCA
Wars2 chr3 98953718 98954556 403,97
Pdlim5 chr3 142035231 142036203 586,07 AGGAACAGAATGTCCCAGAC
4930503B20Rik chr3 146320253 146321062 605,28 AGGTACACAATGTTCCAGCA ATGACTGA
Ror1 chr4 100073937 100075431 416,9
BC051525 chr4 120289222 120289771 765,77 GGGAACACAGAGTCCTGGGC GGGGTGGGGACCTG
Trnp1 chr4 133047438 133048255 385,8 AGCAGGAATGGAATGTTCCT CCCTCCCCCACCCC
Clic4 chr4 134842633 134843533 553,41 CCGCAGAACGCCCTGTACCG CTCTGCCCTACCCA
Srrm1
Kif17 chr4 137834057 137834838 852,11 GGCAGGGACATCATGTTCTT GTGACTCA
Fblim1 chr4 141125723 141126527 262,92 GCCCAGCACCTTCTGTTCCT ACCAACCCCACTCC
H6pd chr4 149353543 149354307 402,8 ATTTCCCCCACACT
Errfi1 chr4 150155907 150156755 334,9 TCCAGCCCCTTCCA
MRPL33 chr5 31936324 31937148 376,22 TAGAACAGAACATCCCTGGG
Dok7 chr5 35480489 35481131 387,2 CAGAGGCACGGAATGTTCCA TGAGTCTC
Tgfbr3 chr5 107552818 107553616 351,82 TAAGAGCACTGGCTGTTCTA TAGGAGGGGCTGGA ATGACTCA
Myo1h chr5 114806421 114807295 303,27 TGCAGGAATGGTATGTACCC
Cdk8 chr5 147072041 147073399 1708,11
Hipk2 chr6 38785066 38785917 297 ATTACTCA
Tra2a chr6 49186023 49186710 636,67
D6Mm5e chr6 82977753 82978472 589,14 GCTGGGAACTCCCTGTACTT
Tead4 chr6 128231964 128232801 315,09 GCAAAGAACTGTCTGTTCCT
Hif3a chr7 17643227 17644190 353,76 GAGGACATTCCGTCCTGTAC AGGGTGGGGGTAGG
Zfp36 chr7 29160976 29161895 509,74 CCGCACATTCCGTCCTCGCC CCCCGCCCCACCCC
Klf13 chr7 71041604 71042464 1831,31 GGCGGGAACAGCATGTTCTC TCTTGCCCAAGCCA
 Nr2f2 chr7 77181488 77182319 277,29 CAAAAGAACAAGCTCTACTT CTGACTCA
Abhd2 chr7 86481426 86482048 713,42 AGGAACACCATGTCTTGGAG AGTGACTCA
AK005418 chr7 117260116 117261077 278,32 TAGTACATTTTGTACTGTAC TGGGTGGGGAGAGA
Copb1 chr7 121346072 121346998 377,11 AGGGAGCACAGTATGTTCCA TGAGTAAC
Adam12 chr7 141428774 141429766 412,02
Hpgd chr8 58899121 58900287 352,74 ATGTACATTCTGTTCTATCC TGACTCA
Fbxo8
Banp chr8 124551887 124552816 494,46 AAGAACAGGCTGTGCTTGGT TGAGTCAG
 Cadm1 chr9 47170289 47170911 709,96 GGCCAGTACAATTTGTTCCT TGGGAGGGGTTAAA TGAGGCAG
Zbtb16 chr9 48531655 48532316 626,54 GGCCAGCACTGCGTGTTCCT
Zbtb16 chr9 48545244 48546123 357,38 GGGTACAGTGTGTTCTTGGA
Zc3h12c chr9 51913134 51914248 461,61 TGCAAGAACCAAATGTTCTC CTGACTCA
Rdx
Gcnt3 chr9 69895308 69896173 418,72 TTGTACATGCAGTCCCTGCA CCCTGCCCAGCCCT
Rpl29 chr9 106314210 106315267 273,93
Cspg5 chr9 110183619 110184270 474,14 AGCGTGGGGACCAT
2610002I17Rik
Lars2 chr9 123370513 123371653 1022,6
Rap2c chrX 48321683 48322064 489,34 GACAAGCACAGGCTGTTCTT
Frmd7
Il1rapl1 chrX 84483527 84484212 539,48
Tsc22d3 chrX 137063416 137064179 433,76 GCAAAAAACAGAATGTTCAG AGGGAGGGGCAGGA TGAGTAAT
Sevilla et al., Table S2.
ChIP-qPCR
Gene Symbol Description Gene Bank Product (bp) Forward primer Reverse primer
Per1 Period circadian clock 1 NM_001159367.1 200 TACAGGACCGCTGTCGTTGGGTCGTCAAAGCGGAGGCAGGAGG
Tsc22d3 TSC22 domain family, member 3 NM_001077364.1 91 GGAGGGAATGCAACTGGGAG CCCCTCCCTTGAATGCTGAA
Zfp36 Zinc finger protein 36 NM_011756.4 180 TCCTCTATCAAGTCCGCCCA AGGAACGGGATGTTTCCGTC
RT-qPCR
Gene Symbol Description Gene Bank Product (bp) Forward primer Reverse primer
Hprt1 (housekeeping) Hypoxanthine phosphoribosyltransferase 1 NM_013556 142 TCAGTCAACGGGGGACATAAA GGGGCTGTACTGCTTAACCAG
Klf4 Kruppel-like factor 4 NM_010637.3 185 GTGCCCCGACTAACCGTTG  GTCGTTGAACTCCTCGGTCT  
Nr3c1 GR alpha NM_008173.3 182 AAAGAGCTAGGAAAAGCCATTGTCAGCTAACATCTCTGGGAATTCA
Per1 Period circadian clock 1 NM_001159367.1 298 GGGAGACAAGAAGCCCCCGGAGTGTCGGCGACCAGGGGGAA
Sprr2d Small proline-rich protein 2d NM_011470.1 336 TGGTACTCAAGGCCGAGA TTTGTCCTGATGACTGCTGAAGAC
Tsc22d3 (Gilz) TSC22 domain family, member 3 NM_001077364.1 111 CTGTTGGCCTCGACTGCTG GCCGAAAGTTGCTCACGAAG
Zfp36 Zinc finger protein 36 NM_011756.4 112 CCACCTCCTCTCGATACAAGA GCTTGGCGAAGTTCACCCA
Supplemental Data Legends. 
Figure S1. Reduced Klf4 expression in GREKO versus CO cells. Klf4 expression was assessed 
in GREKO versus CO cells by RT-QPCR. Mean values ± SD are shown, with asterisks denoting 
statistically significant differences in GREKO relative to CO (Student’s t-test; n=3; *, p<0.05). 
 
Figure S2. Evaluation of GR-Klf4 interaction via co-immunoprecipitation. Lysates of cells 
treated with Dex for 0, 30 or 60 min were subjected to immunoprecipitation with antibody 
specific for Klf4 or a nonspecific rabbit IgG (t0). Input controls and immunoprecipitates were 
analysed by immunoblotting with GR, p-GR and Klf4 antibodies. 
 
Table S1. Annotated genes identified by GR ChIP-seq in MPKs after 2h of Dex treatment. 
Gene symbol, chromosomal location (start and end coordinates), p-value, and over-represented 
GRE, KLF and AP-1 motifs in the genomic sequences are shown. 
 
Table S2. List of primers used for validating the identified GR ChIP-seq targets. 
 
 
